Ascentage Pharma Group International is a biotechnology company that discovers and develops small-molecule targeted therapeutics. The company's core research focuses on apoptosis pathways, aiming to restore the natural cell death process in cancer cells by targeting key proteins such as Bcl-2, IAP, and MDM2-p53. Its lead product, olverembatinib, is a BCR-ABL inhibitor designed to treat drug-resistant chronic myeloid leukemia (CML). Ascentage operates research and development centers in Suzhou, China, and Rockville, Maryland, enabling it to conduct global clinical trials and pursue regulatory approvals in multiple jurisdictions. The company maintains strategic partnerships with global pharmaceutical firms to advance its pipeline of next-generation kinase inhibitors and apoptosis-targeted drugs.
